Predicting Preterm Birth in Seconds

EveryBaby has developed a handheld medical device that assesses a woman's risk of spontaneous preterm birth starting from 14 weeks of pregnancy, delivering a result in seconds with no blood draw and no laboratory processing required. The device uses electrical impedance spectroscopy combined with machine learning to read the cervix directly at the point of care. Our 449-woman clinical study in the UK is complete, and we currently hold conditional regulatory approval in Abu Dhabi. EveryBaby is headquartered in Hong Kong. We are currently raising our seed round to advance further regulatory submissions, expand clinical validation into additional markets, and scale manufacturing ahead of commercial launch. We welcome conversations with investors focused on medtech, diagnostics, and women's health.